BioTime To Present at Regen Med Investor Day March 26 in New York
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 25, 2014--
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, today announced
that Chief Executive Officer Michael D. West, PhD will present at the 2nd
Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in
New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in partnership
with leading financial firms Maxim Group and Piper Jaffray, this one-day
investor conference focuses exclusively on the regenerative medicine and
advanced therapies sector. The event includes clinical and commercial
experts who will be on-hand to address specific questions regarding the
outlook for the industry, as well as offer insight into how regenerative
medicine products could impact the standard of care in key therapeutic
areas. The program will include talks by key opinion leaders in the
industry, life science investment experts and analysts as well as
presentations by more than 30 leading companies from across the globe.
The following are specific details regarding BioTime’s
ARM’s Regen Med Investor Day
March 26, 2014
3:30 – 3:45 p.m. EDT
Metropolitan Club, One East 60th Street, New York, NY 10022
A live-streaming webcast of all panels and company presentations will be
available at: http://www.arminvestorday.com/webcast
and will be published on the event’s website shortly after the
conference. The presentation will also be made available on BioTime's
website at www.biotimeinc.com.
Attendance at this event is for credentialed investors and members of
the media only. If you are interested in attending, please contact Laura
Parsons at firstname.lastname@example.org.
Please visit http://www.arminvestorday.com
for more information.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based
multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate access
to life-giving advances in regenerative medicine and advanced therapies.
ARM also works to increase public understanding of the field and its
potential to transform human healthcare, providing business development
and investor outreach services to support the growth of its member
companies and research organizations. Prior to the formation of ARM in
2009, there was no advocacy organization operating in Washington, DC to
specifically represent the interests of the companies, research
institutions, investors and patient groups that comprise the entire
regenerative medicine community. Today ARM has more than 150 members and
is the leading global advocacy organization in this field. To learn more
about ARM or to become a member, visit www.alliancerm.org.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary PureStem®
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood plasma volume
expander for use in surgery, emergency trauma treatment and other
applications. Hextend® is manufactured and distributed
in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang
Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
• Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired
the stem cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment for
the development of new therapeutic products for regenerative medicine.
• OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
• Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an
Israel-based biotechnology company focused on developing stem cell-based
therapies for retinal and neurological disorders, including the
development of retinal pigment epithelial cells for the treatment of
macular degeneration, and treatments for multiple sclerosis.
• LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and
distributes GeneCards®, the leading human gene
database, as part of an integrated database suite that also includes the LifeMap
Discovery® database of embryonic development, stem cell
research and regenerative medicine, and MalaCards, the human
• ES Cell International Pte Ltd., a Singapore private limited company,
developed clinical and research grade hES cell lines and plans to market
those cell lines and other BioTime research products in over-seas
markets as part of BioTime’s ESI BIO Division.
• BioTime Asia, Limited, a Hong Kong company, may offer and sell
products for research use for BioTime’s ESI BIO Division.
• OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
• ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of cardiovascular and related ischemic disorders, as well as products
for research using cell reprogramming technology.
Additional information about BioTime can be found on the web at www.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
Source: BioTime, Inc.
Lesley Stolz, PhD, 510-521-3390, ext 367
Vice President, Corporate Development
Segall, 510-521-3390, ext 301